Scientist leads successful drug trial for childhood leukaemia

Dec 21, 2010

(PhysOrg.com) -- Research has shown that a new cancer treatment increases survival to almost 70 per cent for children whose acute lymphoblastic leukaemia (ALL) returns.

The study, carried out by Professor Vaskar Saha, who is Cancer Research UK Professor of Paediatric at The University of Manchester, is published online in The Lancet on December 4. The results were so promising that now all children with relapsed ALL are being offered the trial drug Mitoxantrone.

The trial was funded by Cancer Research UK (CRUK) and Leukaemia & Lymphoma Research. Central Manchester University Hospitals NHS Foundation Trust has sponsored the study since early 2010, providing oversight of all the clinical trial processes including the conduct, management and safety of the study.

Patients from Royal Manchester Children’s Hospital have also participated in the trial, and it is supported by the National Institute for Health Research’s Manchester Biomedical Research Centre (MBRC).

Two-hundred-and-sixteen children across the UK, Australia and New Zealand took part in the trial; 111 were given the standard treatment Idarubicin and 105 were given Mitoxantrone. After three years, 69 per cent of children given Mitoxantrone had survived the disease, compared to 45 per cent of those given Idarubicin.

Professor Saha, who is based in the School of Cancer and Enabling Sciences, said: “These striking results show just what a powerful drug Mitoxantrone is in treating children whose leukaemia has returned, offering hope to many families across the country.”

The significant increase in survival seen in this trial has resulted in Mitoxantrone being offered to all children with relapsed ALL since 2008. As well as improving survival, children given Mitoxantrone also experienced fewer side effects.

Over the last 30 years the number of children who have survived ALL has risen from 50 to over 80 per cent but similar improvements have not been seen in children whose cancer returns. It remains the leading cause of cancer death in children, and survival for children whose leukaemia returns had until now remained constant at around 50 per cent.

Professor Saha added: “As a result of this trial, Mitoxantrone is now the standard treatment for relapsed ALL, and is having a significant impact on the number of children who beat the disease worldwide. This is the first time that a trial in ALL has been stopped so early after one drug had such clear benefits for patients.”

Kate Law, director of clinical research at Cancer Research UK, said: “These exciting results highlight the impact that research is continuing to have to help more children beat the disease. Cancer Research UK is the largest funder of research and trials into childhood cancers in the UK. Today, thanks to research like this, more than three quarters of children beat , compared to a quarter in the 1960s.”

Also writing in The , Professor Martin Schrappe of the University Medical Centre Schleswig-Holstein called the outcome "one of the largest improvements ever achieved by a single modification of treatment in childhood ALL".

Explore further: Anti-cancer vaccine proves cost effective, but coverage needs improving

More information: www.thelancet.com/

add to favorites email to friend print save as pdf

Related Stories

Teen cancer survival rates on the rise

Aug 20, 2008

(PhysOrg.com) -- The first national report detailing survival for teenagers and young adults with cancer shows that survival rates climbed by about 11% over two decades. The University of Manchester findings, published in ...

New research provides hope for childhood cancer sufferers

Jul 16, 2007

Scientists investigating drug therapies for children with Acute Lymphoblastic Leukaemia (ALL) have presented new data demonstrating for the very first time that a small molecule called ABT-737 can increase the effectiveness ...

Recommended for you

DNA alternative to Pap smear sparks medical debate (Update)

16 hours ago

A high-tech screening tool for cervical cancer is facing pushback from more than a dozen American patient groups, who warn that the genetic test could displace a simpler, cheaper and more established mainstay of women's health: ...

User comments : 0

More news stories

ESO image: A study in scarlet

This new image from ESO's La Silla Observatory in Chile reveals a cloud of hydrogen called Gum 41. In the middle of this little-known nebula, brilliant hot young stars are giving off energetic radiation that ...

First direct observations of excitons in motion achieved

A quasiparticle called an exciton—responsible for the transfer of energy within devices such as solar cells, LEDs, and semiconductor circuits—has been understood theoretically for decades. But exciton movement within ...

Patent talk: Google sharpens contact lens vision

(Phys.org) —A report from Patent Bolt brings us one step closer to what Google may have in mind in developing smart contact lenses. According to the discussion Google is interested in the concept of contact ...

Warm US West, cold East: A 4,000-year pattern

Last winter's curvy jet stream pattern brought mild temperatures to western North America and harsh cold to the East. A University of Utah-led study shows that pattern became more pronounced 4,000 years ago, ...